STAAHealthcare · Medical Instruments & SuppliesThe 12 Wall Street analysts covering STAAR Surgical Co. hold a median 12-month price target of $28 — +16.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 80 of 100 as at 2 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores STAAR Surgical Co. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (99): Sales and profits are climbing, and climbing faster than before.
Accruals (37): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on STAA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +16.6% from it.
Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Aug 2026 | Stifel | Maintains | Hold | $31 → $28 |
| 13 Aug 2026 | UBS | Maintains | Sell | $20 → $19 |
| 13 Aug 2026 | Wedbush | Maintains | Outperform | $40 → $37 |
| 4 Aug 2026 | Wedbush | Reiterates | Outperform | $40 |
| 4 Aug 2026 | Wedbush | Reiterates | Outperform | — |
| 28 July 2026 | UBS | Initiates | Sell | — |
| 28 July 2026 | UBS | Initiates | Sell | $20 |
| 22 July 2026 | Wedbush | Reiterates | Outperform | — |
| 22 July 2026 | Wedbush | Reiterates | Outperform | $40 |
| 16 July 2026 | Wedbush | Reiterates | Outperform | — |
| 16 July 2026 | Wedbush | Reiterates | Outperform | $40 |
| 29 May 2026 | Wedbush | Reiterates | Outperform | — |
| 15 May 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 14 May 2026 | Canaccord Genuity | Maintains | Buy | — |
| 14 May 2026 | Mizuho | Maintains | Neutral | — |
| 14 May 2026 | Piper Sandler | Maintains | Neutral | — |
| 14 May 2026 | Stifel | Maintains | Hold | — |
| 14 May 2026 | Wedbush | Upgrade | Outperform | — |
| 9 Apr 2026 | Canaccord Genuity | Upgrade | Buy | — |
| 9 Apr 2026 | Wedbush | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. STAA appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 3 Sept 2026, STAAR Surgical Co. returned −13.7% against +21.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 2% of US stocks
Cheaper than 36% of US stocks
Cheaper than 32% of US stocks
Cheaper than 16% of US stocks
Higher than 93% of US stocks
Higher than 86% of US stocks
Higher than 86% of US stocks
Higher than 65% of US stocks
Higher than 50% of US stocks
Higher than 46% of US stocks
Higher than 79% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
STAAR Surgical Co. has a market value of $1.2B and an enterprise value of $987.2M.
Revenue in the twelve months to 31 Mar 2026: $290.4M. The latest quarter grew 111.0% year on year.
Net income over the same four quarters: −$21.0M, a −7.2% net margin.
Diluted earnings per share, trailing twelve months: $−0.43.
Free cash flow in the twelve months to 31 Mar 2026: −$55.0M, after $4.8M of capital spending.
STAAR Surgical Co. spent $8.6M on share buybacks in the twelve months to 31 Mar 2026.
Trailing P/E: 294.0×; forward P/E: 23.0× — the forward figure prices analyst consensus estimates, not reported earnings.
STAAR Surgical Co. employs 921 people — $315K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own STAAR Surgical Co. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
STAAR Surgical has appointed Ben Park, Ph.D., as its new Chief Technology Officer. Dr. Park will join the company's Executive Committee and report to CEO Warren Foust.
Why it matters — The appointment brings a medtech innovator and platform builder to STAAR as it aims to evolve from a single-product focus into a multi-product platform.
Zacks Investment Research published a review of STAAR Surgical's (STAA) international revenue performance and how those trends influence Wall Street analysts' forecasts and the stock's future prospects.
Why it matters — A STAA watcher would care because international revenue trends are central to analysts' predictions about the company's future performance and stock outlook.
STAAR Surgical reported second-quarter 2026 net sales of $93.5 million, up 111% from $44.3 million a year earlier. CEO Warren Foust attributed the growth to contributions from China, the Americas and parts of Europe, and called it the company's strongest first half of revenue performance.
Why it matters — The report highlights strong revenue growth across key markets, indicating robust demand for STAAR Surgical's products during the period.
STAAR Surgical Company (STAA) published the transcript of its Q2 2026 earnings call, as covered by Seeking Alpha. The item presents the transcript of the company's second-quarter 2026 earnings discussion.
Why it matters — A STAA watcher would care because the transcript provides management's direct commentary on the company's quarterly performance and outlook.
Staar Surgical reported quarterly earnings of $0.31 per share, surpassing the Zacks Consensus Estimate of $0.21 per share. This compares with a loss of $0.07 per share in the same quarter a year ago.
Why it matters — The company beat analyst expectations for both earnings and revenue, marking a notable improvement from a year-ago loss.
The 12 Wall Street analysts covering STAAR Surgical Co. have a median 12-month price target of $28, with estimates ranging from $19 to $37. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering STAAR Surgical Co., 3 rate it a Buy, 8 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks STAAR Surgical Co. 80 out of 100 across roughly 4,600 US stocks as at 2 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 2 Sept 2026, STAAR Surgical Co. ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +16.6% from the last close, and Ticker Nerd's factor model ranks STAAR Surgical Co. 80 out of 100 as at 2 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering STAAR Surgical Co. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for STAA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $19 to $37 over the next 12 months.
STAAR Surgical Co. returned -13.7% over the 12 months to 3 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
STAAR Surgical Company is a medical technology company that designs, develops, manufactures, and markets implantable lenses for the eye and companion delivery systems. Its core product line includes Implantable Collamer® Lenses used in refractive surgery to address visual disorders such as myopia, hyperopia, astigmatism, and presbyopia.
The most recent item we track (Business Wire, 2 Sept 2026): "STAAR Surgical Names Medtech Innovator and Platform Builder Ben Park as Chief Technology Officer". STAAR Surgical has appointed Ben Park, Ph.D., as its new Chief Technology Officer. Dr. Park will join the company's Executive Committee and report to CEO Warren Foust.
STAAR Surgical Company is a medical technology company that designs, develops, manufactures, and markets implantable lenses for the eye and companion delivery systems. Its core product line includes Implantable Collamer® Lenses used in refractive surgery to address visual disorders such as myopia, hyperopia, astigmatism, and presbyopia. The company focuses on ophthalmic surgery solutions that are used by eye care professionals seeking lens-based vision correction options. STAAR Surgical also offers accessory systems that support lens implantation procedures and help deliver its products into the eye. Headquartered in Lake Forest, California, and founded in 1982, STAAR Surgical serves a global market centered on eye care and vision correction, with a business model built around specialized surgical devices and related procedure support.
CEO Mr. Warren Foust · 921 employees · United States · https://www.staar.com
